Lupin Limited announced that its subsidiaries in the Philippines (Multicare Pharmaceuticals) and Brazil (MedQuimica) have entered into an exclusive licensing agreement with Neopharmed Gentili S.p.A., an Italian pharmaceutical company. This agreement grants Lupin the marketing and promotional rights for the gastroenterology brand Plasil® (metoclopramide) in these two key emerging markets. Under the terms of the agreement, Neopharmed will be responsible for the product supply in the Philippines, ensuring adherence to global quality standards. In Brazil, the production of Plasil® will be transferred to MedQuimica's manufacturing facility. This strategic partnership aims to enhance Lupin’s gastroenterology portfolio and expand its footprint in these significant markets. Fabrice Egros, President of Corporate Development at Lupin, stated that the partnership is a significant milestone in expanding access to Plasil®, an effective anti-emetic treatment, across emerging markets. He highlighted the combined strengths of Lupin's local presence and commercial capabilities with Neopharmed's distribution network. Matteo Meazzini, Director of Business Development at Neopharmed Gentili, expressed pleasure in partnering with Lupin to bring Plasil® to Brazil and the Philippines, emphasizing the expansion of Neopharmed's international reach.